Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2020-12-01 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is a regulatory notification from AstraZeneca PLC regarding its total voting rights and issued share capital, filed in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of disclosure is a standard regulatory requirement for companies to inform shareholders of the denominator for calculating interest notifications. Since it does not fit into specific categories like 'Major Shareholding Notification' (which is for individual investors) or 'Share Issue' (which is for specific capital changes), it falls under the general regulatory filing category.
2020-12-01 English
Block listing Interim Review
Share Issue/Capital Change Classification · 99% confidence The document is explicitly titled 'BLOCK LISTING SIX MONTHLY RETURN' and is distributed via 'RNS Number'. It details the balance and movement of unallotted securities under various share option plans over a specific period (1 June 2020 to 30 November 2020). This type of filing, which reports on the status of securities reserved for employee share schemes, is a routine regulatory disclosure. Since it is a specific regulatory filing that doesn't fit the definitions for 10-K, AR, ER, or IR, and it is not an announcement of a report (RPA), the most appropriate general category for routine regulatory disclosures not covered elsewhere is 'Regulatory Filings' (RNS).
2020-12-01 English
CRESTOR TO BE DIVESTED TO GRUNENTHAL IN EUROPE
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content describes a divestment transaction involving the sale of rights to a drug (Crestor) to another company (Grünenthal). It includes details about the transaction, financial considerations, and regulatory clearances. There are no financial statements or detailed financial performance data presented, only a description of the transaction and its expected impact. Form 6-K filings are typically used for current reports by foreign private issuers and are considered regulatory filings. The document is not an annual or interim report, earnings release, or any other detailed financial report. It is an announcement of a corporate transaction and related information, fitting best under Regulatory Filings (RNS). The document length is about 4907 characters, which is not extremely short, but the content is clearly a regulatory announcement rather than a full report or presentation.
2020-12-01 English
Crestor to be divested to Grünenthal in Europe
M&A Activity Classification · 99% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) on December 1, 2020. It details a specific corporate transaction: AstraZeneca selling the rights to the drug Crestor in specific European countries to Grünenthal for a cash payment ($320m upfront plus potential milestones). This type of announcement, concerning the divestment of assets or significant business transactions, falls under the category of Merger & Acquisition (M&A) activity or a major corporate transaction. Given the specific definitions, 'M&A Activity (Code: TAR)' is the most appropriate fit for a divestment/sale of a business unit or major asset, even though it is not a traditional merger or takeover bid. The document structure (RNS header, brief summary, financial considerations, closing details) is typical of a regulatory disclosure about a transaction. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). Since it is a specific transaction announcement, TAR is preferred over the general RNS fallback.
2020-12-01 English
FORXIGA APPROVED IN JAPAN FOR CHRONIC HEART FAILURE
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The content focuses on the announcement of the approval of Forxiga in Japan for chronic heart failure, including clinical trial results and company information. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. The document is an announcement of a regulatory and product approval event rather than a financial report or management discussion. Given the nature of the filing (Form 6-K) and the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (12,423 characters) is substantial, indicating it is not a brief announcement but still not a financial report. Therefore, the classification is RNS with high confidence.
2020-11-30 English
Forxiga approved in Japan for heart failure
Regulatory Filings Classification · 100% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number : 8900G' header and the concluding paragraph stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a specific regulatory event: the approval of the drug Forxiga in Japan for chronic heart failure. This type of material—a press release announcing a significant corporate or regulatory event via an official news service—fits best under the general 'Regulatory Filings' category (RNS) or potentially an 'Earnings Release' (ER) if it contained financial results, but since it is a product approval announcement distributed via RNS, RNS is the most appropriate general classification, especially given the explicit RNS formatting and footer. It is not a full Annual Report (10-K), an Interim Report (IR), or a specific management/board change (MANG). Since it is a direct announcement distributed through the RNS system, the code RNS is selected.
2020-11-30 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.